Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.13% | -18.82% | 2.67% | -20.45% | -13.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.13% | -18.82% | 2.67% | -20.45% | -13.99% |
| Cost of Revenue | 49.48% | -8.68% | -5.84% | -19.09% | -28.51% |
| Gross Profit | 4.76% | -19.20% | 3.08% | -20.51% | -13.44% |
| SG&A Expenses | 12.25% | -0.90% | -15.83% | 16.16% | -9.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.00% | 3.58% | -15.86% | 10.26% | -9.82% |
| Operating Income | -33.42% | -71.84% | 112.78% | -66.84% | -34.42% |
| Income Before Tax | -62.92% | -62.86% | 100.77% | -64.87% | 3.09% |
| Income Tax Expenses | -55.78% | -64.61% | -70.96% | -70.80% | -28.17% |
| Earnings from Continuing Operations | -65.27% | -62.42% | 100.56% | -61.97% | 20.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.28% | 56.89% | -2,203.45% | 50.99% | 47.31% |
| Net Income | -87.47% | -64.18% | 99.90% | -71.73% | 90.39% |
| EBIT | -33.42% | -71.84% | 112.78% | -66.84% | -34.42% |
| EBITDA | -19.40% | -66.91% | 123.23% | -63.85% | -34.05% |
| EPS Basic | -87.89% | -65.52% | 99.91% | -79.04% | 41.92% |
| Normalized Basic EPS | -90.85% | -66.82% | 97.81% | -85.74% | 19.71% |
| EPS Diluted | -63.33% | -86.39% | 99.76% | -73.80% | -70.00% |
| Normalized Diluted EPS | -90.51% | -65.40% | 97.81% | -85.21% | 23.98% |
| Average Basic Shares Outstanding | 4.23% | 3.79% | 18.45% | 34.68% | 34.46% |
| Average Diluted Shares Outstanding | 0.49% | -0.61% | 18.45% | 30.08% | 29.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |